Tyler Rehbein,Tong Tong Wu,Simona Treidler,Davide Pareyson,Richard Lewis,Sabrina W Yum,Brett A McCray,Sindhu Ramchandren,Joshua Burns,Jun Li,Richard S Finkel,Steven S Scherer,Stephan Zuchner,Michael E Shy,Mary M Reilly,David N Herrmann,Julian Blake,Kayla Cornett,Thomas O Crawford,Federica Rachele Danti,Gabrielle Donlevy,Katy Eichinger,Tim Estilow,Shawna M E Feely,Matilde Laura,Manoj Menezes,Isabella Moroni,Chiara Pisciotta,Alex Rossor,Gita Ramdharry,Paola Saveri,Giulia Schirinzi,Rosemary R Shy,Mariola Skorupinska,Janet E Sowden,Charlotte J Sumner,Dragan Vujovic,Inherited Neuropathy Consortium-Rare Diseases Clinical Research Network (INC-RDCRN)

Abstract:Recessive SH3TC2 variants cause Charcot-Marie-Tooth disease type 4C (CMT4C). CMT4C is typically a sensorimotor demyelinating polyneuropathy, marked by early onset spinal deformities, but its clinical characteristics and severity are quite variable. Clear relationships between pathogenic variants and the spectrum of disease manifestations are to date lacking. Gene replacement therapy has been shown to ameliorate the phenotype in a mouse model of CMT4C, emphasizing the need for natural history studies to inform clinical trial readiness. Data, including both genetic information and clinical characteristics, were compiled from the longitudinal, prospective dataset of the Inherited Neuropathy Consortium, a member of the Rare Diseases Clinical Research Network (INC-RDCRN). The Charcot Marie Tooth Neuropathy Score (CMTNS), Examination Score (CMTES) and the Rasch-weighted CMTES (CMTES-R) were used to describe symptoms, neurologic examinations, and neurophysiologic characteristics. Standardized response means were calculated at yearly intervals and a mixed model for repeated measures was used to estimate the change in CMTES and CMTES-R over time. 56 individuals (59% female), median age 27 years (range 2–67 years) with homozygous or compound heterozygous variants in SH3TC2 were identified, including 34 unique variants, 14 of which have not previously been published. 28 participants had longitudinal data available. While there was not a significant difference in the CMTES in those with protein-truncating versus non-protein-truncating variants, there were significant differences in the mean ulnar nerve compound muscle action potential amplitude, the mean radial sensory nerve action potential amplitude, and in the prevalence of scoliosis, suggesting the possibility of a milder phenotype in individuals with one or two non-protein-truncating variants. Overall, the mean value of the CMTES was 13, reflecting moderate clinical severity. There was a high rate of scoliosis (81%), scoliosis surgery (36%), and walking difficulty (94%) among study participants. The CMTES and CMTES-R appeared moderately responsive to change over extended follow-up, demonstrating a standardized response mean of 0.81 standard deviation units or 0.71 standard deviation units respectively, over 3 years. Our analysis represents the largest cross-sectional and only longitudinal study to date, of the clinical phenotype of both adults and children with CMT4C. With the promise of upcoming genetic treatments, this data will further define the natural history of the disease and inform study design in preparation for clinical trials.

Diagnostic neuromuscular ultrasound to confirm clinical significance of a genetic variant for Charcot-Marie-Tooth type 4C: A case report

Genetic Spectrum of MCM3AP and Its Relationship with Phenotype of Charcot‐Marie‐Tooth Disease

A Novel Mutation of LRSAM1 in a Chinese Family with Charcot-Marie-Tooth Disease

[Analysis of the Pathological Features and Gene Mutations of Chinese Patients with Charcot-Marie-Tooth Disease].

Clinical Analysis of a Charcot-Marie-Tooth Disease Type 2F Family in China

Author Response for "genetic Spectrum and Clinical Profiles in a Southeast Chinese Cohort of Charcot‐Marie‐Tooth Disease"

Targeted next-generation sequencing panels in the diagnosis of Charcot-Marie-Tooth disease

Clinical,pathological and Genetic Studies in a Chinese Charcot-Marie-Tooth Disease Type 2 Family

Peripheral nerve ultrasound in pediatric Charcot-Marie-Tooth disease type 1A

Assessment of Targeted Next-Generation Sequencing as a Tool for the Diagnosis of Charcot-Marie-Tooth Disease and Hereditary Motor Neuropathy

The Role of Neuromuscular Ultrasound in the Diagnosis of Peripheral Neuropathy

Neuropathy due to bi-allelic SH3TC2 variants: Genotype-phenotype correlation and natural history

Case Report: Charcot-marie-tooth disease caused by a de novo MORC2 gene mutation - novel insights into pathogenicity and treatment

Next-generation sequencing in Charcot–Marie–Tooth disease: opportunities and challenges

Improving molecular diagnosis of Chinese patients with Charcot-Marie-Tooth by targeted next-generation sequencing and functional analysis.

Clinical and Pathological Features in Charcot-Marie-Tooth Disease Type 2A2: a Family Report

Neuromuscular ultrasound in combination with nerve conduction studies helps identify inflammatory motor neuropathies from lower motor neuron syndromes

Sural Biopsy To Detect The Axonal Cytoskeleton Defects In Kif5a-Related Charcot-Marie-Tooth Disease Type 2

Intermediate conduction velocity in two cases of Charcot−Marie−Tooth disease type 1A

Ultrasonographic manifestations of Charcot-Marie-Tooth disease due to a mutation in the PMP22 gene: A case image

Whole-Genome Sequencing in A Patient with Charcot-Marie-Tooth Neuropathy.